Literature DB >> 23763889

Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review.

Arti Parekh1, Powell L Graham, Paul L Nguyen.   

Abstract

The National Comprehensive Cancer Network guidelines currently endorse salvage local therapy as a reasonable alternative to observation or androgen-deprivation therapy for select men with a biopsy-proven local recurrence after definitive radiation for prostate cancer. Patients being considered for salvage therapy should have had localized disease at presentation, a prostate-specific antigen < 10 at recurrence, a life expectancy >10 years at recurrence, and a negative metastatic workup. In this systematic review, we synthesize the current literature describing the oncologic efficacy and toxicity profile of salvage brachytherapy, prostatectomy, cryotherapy, and high-intensity focused ultrasound. We found 5-year biochemical control rates to be similar across treatments, in the range of 52%-56%, although patient selection and definition of failure was variable. Toxicity profiles were also distinct between local salvage modalities.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23763889     DOI: 10.1016/j.semradonc.2013.01.006

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  13 in total

1.  Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.

Authors:  Amar U Kishan; Sang J Park; Christopher R King; Kristofer Roberts; Patrick A Kupelian; Michael L Steinberg; Mitchell Kamrava
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

2.  Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes.

Authors:  Brecht Devos; Walid Al Hajj Obeid; Colin Andrianne; Romain Diamand; Alexandre Peltier; Wouter Everaerts; Hein Van Poppel; Roland Van Velthoven; Steven Joniau
Journal:  World J Urol       Date:  2019-01-21       Impact factor: 4.226

Review 3.  Salvage local therapy for radiation-recurrent prostate cancer - where are we?

Authors:  Romuald Zdrojowy; Janusz Dembowski; Bartosz Małkiewicz; Krzysztof Tupikowski; Wojciech Krajewski
Journal:  Cent European J Urol       Date:  2016-07-04

Review 4.  Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review.

Authors:  D A Smit Duijzentkunst; M Peters; J R N van der Voort van Zyp; M A Moerland; M van Vulpen
Journal:  World J Urol       Date:  2016-03-24       Impact factor: 4.226

5.  Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells.

Authors:  Yongqing Liu; Chunwen Yue; Juan Li; Jing Wu; Shikang Wang; Deqing Sun; Yanxia Guo; Zhaomin Lin; Denglu Zhang; Rongmei Wang
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

Review 6.  Management of bladder neck stenosis and urethral stricture and stenosis following treatment for prostate cancer.

Authors:  Helen L Nicholson; Yasser Al-Hakeem; Javier J Maldonado; Vincent Tse
Journal:  Transl Androl Urol       Date:  2017-07

7.  Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.

Authors:  Aurélie Mbeutcha; Laurent Chauveinc; Pierre-Yves Bondiau; Marie-Eve Chand; Matthieu Durand; Daniel Chevallier; Jean Amiel; Daniel Lam Cham Kee; Jean-Michel Hannoun-Lévi
Journal:  Radiat Oncol       Date:  2017-03-09       Impact factor: 3.481

8.  Prostate Cancer - Local Treatment after Radiorecurrence: Surgery - Back to the future?

Authors:  Leonardo O Reis; Paul L Nguyen
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

9.  Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Shunta Hori; Yosuke Morizawa; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Nagaaki Marugami; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  J Contemp Brachytherapy       Date:  2017-07-27

10.  Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design.

Authors:  Willemien van den Bos; Berrend G Muller; Daniel M de Bruin; Andre Luis de Castro Abreu; Christian Chaussy; Jonathan A Coleman; Antonio Finelli; Inderbir S Gill; Mitchell E Gross; Sjoerd F M Jenniskens; Frank Kahmann; M Pilar Laguna-Pes; Ardeshir R Rastinehad; Lucy A Simmons; Tullio Sulser; Arnauld Villers; John F Ward; Jean J M C H de la Rosette
Journal:  Urol Oncol       Date:  2015-07-29       Impact factor: 2.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.